Navigation Links
Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Date:8/27/2007

Princeton, N.J., Aug. 27 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today that the company will assist the World Health Organization's Special Program for Research and Training in Tropical Diseases (WHO/TDR) in its efforts to develop novel antimalarial agents. Pharmacopeia will receive funding to conduct medicinal chemistry research on compounds identified through WHO/TDR's drug screening program involving a network of centers in developed and developing countries. The goal of this project is to identify new lead series with the potential to become novel malaria drug candidates. Malaria kills more than one million people a year, with most of those being children in the developing world.

For more information about Pharmacopeia, please visit http://www.pharmacopeia.com.

Contact:

Amy Sharpless

609-452-3643

ir_pr@pcop.com


'/>"/>
SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
3. MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting
4. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
5. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
6. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
7. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
9. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
10. Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...re-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX )...ncial results for the second quarter ended October... on Wednesday, November 18, 2009 at 5:00 PM EST. ...uss those results on Thursday, November 19, 2009 a...rter Results Conference Call Instructions ,, ...
(Date:11/6/2009)...re-FirstCall/ -- Caraco Pharmaceutical Laboratorie...tromethamine ophthalmic solution, 0.5% following a...ration (FDA) for Sun Pharma,s Abbreviated New Drug...lmic solution on the first day following patent ex...cally equivalent to Acular® Ophthalmic Soluti...
(Date:11/5/2009)...PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: ...c products for regenerative healing, today reporte...ptember 30, 2009. ,, "During the third quarter ... new biologic products MagniFuse(TM) Bone Graft, ... Innovative Grafting," said Sam Owusu-Akyaw, Presi...
Breaking Medicine Technology:Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Osteotech Reports Third Quarter 2009 Financial Results 2Osteotech Reports Third Quarter 2009 Financial Results 3Osteotech Reports Third Quarter 2009 Financial Results 4Osteotech Reports Third Quarter 2009 Financial Results 5Osteotech Reports Third Quarter 2009 Financial Results 6Osteotech Reports Third Quarter 2009 Financial Results 7Osteotech Reports Third Quarter 2009 Financial Results 8New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 58329 1New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 58329 2New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 58329 3New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 58329 4New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 58329 5Social background weighs heavily on teenage diet 58327 1Social background weighs heavily on teenage diet 58327 2New Treatment May Beat Melanoma 58326 1New Treatment May Beat Melanoma 58326 2New Treatment May Beat Melanoma 58326 3
...rk Hurtt, Chief Medical Officer, to present interi... Trial in Acute Spinal Cord Injury, HOPKINTON, Ma...(Nasdaq: ALSE ) announced that on April 15, 2008,...ss the CETHRIN development,program as a member of ...ing a congressional briefing on Capitol Hill focus...
...EGO, April 9, 2008 Favrille, Inc.,(Nasdaq: FVRL ...specific,active immunotherapies for the treatment ... data cutoff date for the Company,s Phase 3 regist...merly FavId(R)) following,Rituxan(R) in patients w....,As of the data cutoff date, 205 of the 349 patie...
Other Medicine Technology:Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008 2Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008 3Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008 4Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June 2Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June 3Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June 4Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June 5
(Date:11/9/2009)...swire/ -- HUYA Bioscience International, a leade...ion, today announced a strategic partnership with ...ity of China. The agreement is another in a series...China,s leading research and development instituti...t and commercialization of novel biopharmaceutical...
(Date:11/9/2009)...y involving 2,453 women ages 18 to 68 found that l...a partner contributed to higher ratings of pleasur...have long been recommended to women to improve the...isk of vaginal tearing, yet strikingly little avai...ts or associated vaginal symptoms. , The study,...
(Date:11/8/2009)...Newswire-USNewswire/ -- The American Public Health...llness provisions in the health reform bill passed...his bill, the House takes important steps toward u...reforms and moving our health system from one that...on keeping people healthy," said Georges C. Benjam...
(Date:11/8/2009)... out of the game later, doctors say , , ...re the talk of the NFL this season, sidelining suc...k Willie Parker. , Officials at the American Po...f Podiatric Sports Medicine are warning athletes t...ts like football and lacrosse. , "Many fall spo...
(Date:11/8/2009)...book called "Preventing and Healing AIDS Thro...o shows that AIDS is a result of multiple, repeate...mmune system stressor agents, which can be either ...motional. , Oakland, CA ... 2009, cell biologists, physicians, chemists and o...
Breaking Medicine News(10 mins):Health News:HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 3Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2Health News:Rx for Fall Foot Injuries 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3
...0 Jobs, HARRISBURG, Pa., Dec. 28 /PRNewswire-USNe...e Williamsport Hospital and Medical Center campus,... a $12.5 million grant,from the commonwealth, the ...ears -- for debt service to the Lycoming County In...
...,Acquisition Corp. ("Echo" or the "Company") (OTC ...unced at its special meeting of stockholders today... provide stockholders,additional time to consider ...us previously mailed to Echo stockholders.,The Ech...
...ission,to provide service, support and hope to all... America (LFA) submitted comments today to Commiss...stration (SSA), regarding a,proposed change to the...be submitted 5 days,before an administrative heari...
...helped for at least a decade , , FRIDAY, D...ly and safely corrects severe myopia for at least ...pia, which is caused by excessive curving of the e...from some degree of nearsightedness. , Laser surge...
...Year,s as the,"world championship" of weight loss,...nd promises. For millions of well-intentioned diet... and, ultimately,disappointment., (See video fro...mber,by Harris Interactive(R) on behalf of GlaxoSm...
... A review published in Dermatologic Therapy revea... procedures in the same way as women but require h...here has recently become a growing interest in cos... often require more units of Botox than women whic...
Other Medicine News:Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4, 2008 2Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4, 2008 3Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4, 2008 4Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4, 2008 5Health News:Lupus Foundation of America Urges Social Security Administration Not to Adopt Proposed 5-Day Rule 2Health News:Laser Surgery Can Correct Nearsightedness 2Health News:VIDEO from Medialink and GlaxoSmithKline: Really Think You Can 'Lose 30 Pounds in 30 Days?' 2
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
Medicine Products: